Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Popov

Showing results (431-440 of 434) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 434 results.
American Journal of Hematology|January 24, 2024
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLLA Campanella, A Capasso, S Heltai, et al.
Terapevticheskii Arkhiv|March 15, 2021
[Risk factors for the early development of septic shock in patients with severe COVID-19]P V Glybochko, V V Fomin, S V Moiseev, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Hemasphere|September 18, 2024
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLLThomas Chatzikonstantinou, Lydia Scarfò, Eva Minga, et al.
Pageof 44

Showing results (431-440 of 434) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 434 results.
American Journal of Hematology|January 24, 2024
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLLA Campanella, A Capasso, S Heltai, et al.
Terapevticheskii Arkhiv|March 15, 2021
[Risk factors for the early development of septic shock in patients with severe COVID-19]P V Glybochko, V V Fomin, S V Moiseev, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Hemasphere|September 18, 2024
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLLThomas Chatzikonstantinou, Lydia Scarfò, Eva Minga, et al.
Pageof 44